We're talking about steroid-refractory aGvHD and the important parameter of time - an improved product that's been available in an EAP, potential investigators becoming familiar with it and the approval of Ruxolitinib based on Reach1 whose results were truly appalling.
May I ask why you insist on pushing the narrative that SI avoided doing a "proper" when you've admitted to me you don't know whether or not KOL Dr. Susan Prockop was asked if she'd run one?
Taken up the entitlement?, page-409
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.120(9.76%) |
Mkt cap ! $1.267B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.20 | $1.11 | $14.06M | 12.25M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 168043 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 27647 | 1 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.12 |
Change
-0.120 ( 9.28 %) |
||||
| Open | High | Low | Volume | ||
| $1.20 | $1.20 | $1.12 | 1823761 | ||
| Last updated 15.59pm 30/05/2024 ? | |||||
| MSB (ASX) Chart |